Hms GmbH
- Address
- lock Available on a paid plan
Immune System Diseases
The site concentrates on immune‑mediated skin disorders, aiming to test new systemic agents and assess long‑term safety for conditions such as hidradenitis suppurativa and severe plaque psoriasis.
- Upadacitinib efficacy in moderate‑to‑severe hidradenitis suppurativa
- Spesolimab long‑term safety after previous exposure
- Lutikizumab treatment of hidradenitis signs and symptoms
- Remibrutinib impact on hidradenitis activity
- LAD328 proof‑of‑concept in adult hidradenitis patients
Hms GmbH in Merzig supports these investigations with a focused team of two investigators.
Skin and Connective Tissue Diseases
Research at this centre targets psoriasis, atopic dermatitis, and actinic keratosis, evaluating both topical and oral therapies to improve skin health and reduce disease burden.
- JNJ‑77242113 for moderate‑to‑severe plaque psoriasis
- Tirbanibulin versus diclofenac for actinic keratosis on face and scalp
- Deucravacitinib compared with ustekinumab for plaque psoriasis
- Ruxolitinib 1.5% cream for hidradenitis lesions
- RO7790121 achieving EASI‑75 response in atopic dermatitis
The Merzig facility provides a patient‑friendly environment for participants across Germany.
Immune System Phenomena
Studies explore immune response modulation and vaccine safety in dermatologic conditions, seeking to understand how targeted therapies affect underlying immunologic pathways.
- Safety and immunologic response of SHIngrix vaccination in psoriasis or psoriatic arthritis
- Remibrutinib evaluation of cytokine inhibition in hidradenitis
- Assessment of cardiovascular safety of long‑term deucravacitinib use
Findings aim to guide clinicians on balancing efficacy with immune‑related risks.
Immune system processes
The program investigates JAK inhibition and related pathways, focusing on sustained safety and therapeutic benefit for chronic inflammatory skin diseases.
- Long‑term extension study of oral povorcitinib in hidradenitis
- Selective treatment of oral povorcitinib rollover evaluation
- IC0624 first‑line therapy trial for mild‑to‑moderate hidradenitis
Both adult and adolescent participants are included to broaden the relevance of the results.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 therapeutic areas and 15 of 21 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 7 by active trials.
- 1Incyte Corp.1active
lock +6 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Incyte Corp.4trials
lock +6 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hms GmbH
lock Showing 1 of 20 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2 Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LAD328 in Adults with Moderate to Severe Hidradenitis Suppurativa | Almirall S.A. | Phase II | Recruiting | Apr 2026 | — |
IMP list
lock Showing 1 of 21 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| 4-[3-(Cyanomethyl)-3-(3',5'-Dimethyl-1H,1'H-[4,4'-Bipyrazol]-1-Yl)Azetidin-1-Yl]-2,5-Difluoro-N-[(2S)-1,1,1-Trifluoropropan-2-Yl]Benzamide | 3 | Unknown | 2023-06-02 | 2025-09-03 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.